Incremental Value of Genotype Bins over the HAS-BLED Score for the Prediction of Bleeding Risk in Warfarin-Treated Patients with Atrial Fibrillation

Table 2

Bleeding events according to the HAS-BLED score and genotype bins defining warfarin response.

	All patients (n = 526)	Any clinical relevant bleeding event (n = 67)		Major bleeding event (n = 18)
		n (%)		n (%)
HAS-BLED score
0	102 (19.39)	9 (8.82)		2 (1.96)
1	177 (33.65)	18 (10.17)		4 (2.26)
2	135 (25.67)	14 (10.37)		3 (2.22)
3	82 (15.59)	16 (19.51)		6 (7.32)
≥4	30 (5.70)	10 (33.33)	0.001	3 (10)	0.06
HAS-BLED score <3	414 (78.71)	41 (9.90)		9 (2.17)
HAS-BLED score ≥3	112 (21.29)	26 (23.21)	0.0003	9 (8.04)	0.005
Genotype bins defining warfarin response
Normal responder	64 (12.17)	6 (9.37)		1 (1.56)
Sensitive responder	422 (80.23)	48 (11.37)		13 (3.08)
Highly sensitive responder	40 (7.60)	13 (32.5)	^§0.0002	4 (10.00)	^§0.03

value indicating the comparison of the bleeding incidence rate among the different accumulated points of the HAS-BLED score. Comparison between patients with a HAS-BLED score <3 and patients with a HAS-BLED score ≥3. ^§Comparison among patients with different genotype bins defining warfarin response (normal responders (carriers of CYP2C911 + VKORC1-1639G/G, CYP2C911 + VKORC1-1639G/A, or CYP2C913 + VKORC1-1639G/G), sensitive responders (carriers of CYP2C9 11 + VKORC1-1639A/A or CYP2C9 13 + VKORC1-1639G/A), and highly sensitive responders (carriers of CYP2C9 13 + VKORC1-1639A/A, CYP2C933 + VKORC1-1639 A/A, CYP2C933 + VKORC1-1639G/A, or CYP2C933 + VKORC1-1639G/G).